Medical Uses Bimatoprost Lumigan CAS NO.155206-00-1 CAS NO.155206-00-1
- FOB Price: USD: 1.00-2.00 /Metric Ton Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: T/T,Other
- Available Specifications:
EP/BP/USP(1-10)Metric TonEP/BP/USP(11-100)Metric Ton
- Product Details
Keywords
- 155206-00-1
- 155206-00-1
- 155206-00-1
Quick Details
- ProName: Medical Uses Bimatoprost Lumigan CAS ...
- CasNo: 155206-00-1
- Molecular Formula: C25H37NO4
- Appearance: White powder
- Application: Food/Medicine/Industria grade
- DeliveryTime: Wihtin 5-7 Days
- PackAge: A variety of packing ways for your cho...
- Port: Wuhan / Shanghai / Guangzhou ...
- ProductionCapacity: 500~1000 Kilogram/Month
- Purity: 99%
- Storage: Kept in a well-closed, light-resistant...
- Transportation: "1,Best Quality: Our products have ex...
- LimitNum: 1 Kilogram
- Moisture Content: 0.001
- Impurity: 0.001
Superiority
Details
Bimatoprost Basic information |
Product Name: | Bimatoprost |
Synonyms: | N-ETHYL-9ALPHA,11ALPHA,15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDE;LUMIGAN;BIMATOPROST;BIMATOPROST(TM);17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE;BIMATOPROST(LUMIGAN);17-phenyl-tri-norprostaglandin f2α-ethyl amide;(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide |
CAS: | 155206-00-1 |
MF: | C25H37NO4 |
MW: | 415.57 |
EINECS: | |
Product Categories: | Prostaglandins;Prostaglandin;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Arachidonic Acid Cascade;Lipids in Cell Signaling;Lumigan;Inhibitors |
Bimatoprost Chemical Properties |
mp | 66-68°C |
storage temp. | −20°C |
form | solid |
CAS DataBase Reference | 155206-00-1 |
Bimatoprost (marketed in the US, Canada and Europe by Allergan, under the trade name Lumigan) is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes.[1] In December 2008, the indication to lengthen eyelashes was approved by the U.S. Food and Drug Administration (FDA);